Abstract:<p>Cancer metastasis to distant organs is initiated by tumor cells that disseminate from primary heterogeneous tumors. The subsequent growth and survival of tumor metastases depend on different metabolic changes, which constitute one of the enigmatic properties of tumor cells. Aerobic glycolysis, 'the Warburg effect', contributes to tumor energy supply, by oxidizing glucose in a faster manner compared to oxidative phosphorylation, leading to an increased lactate production by lactate dehydrogenase A (LDH-A), which in turn affects the immune response. Surrounding stromal cells contribute to feedback mechanisms further prompting the acquisition of pro-invasive metabolic features. Hence, therapeutic strategies targeting the glycolytic pathway are intensively investigated, with a special interest on their anti-metastatic properties. Various small molecules, such as LDH-A inhibitors, have shown pre-clinical activity against different cancer types, and blocking LDH-A could also help in designing future complimentary therapies. Modulation of specific targets in cells with an altered glycolytic metabolism should indeed result in a milder and distinct toxicity profile, compared to conventional cytotoxic therapy, while a combination treatment with vitamin C leading to increasing reactive oxygen species levels, should further inhibit cancer cell survival and invasion. In this review we describe the impact of metabolic reprogramming in cancer metastasis, the contribution of lactate in this aberrant process and its effect on oncogenic processes. Furthermore, we discuss experimental compounds that target glycolytic metabolism, such as LDH-A inhibitors, and their potential to improve current and experimental therapeutics against metastatic tumors.</p>

Inhibition of lactate dehydrogenase activity as an approach to cancer therapy

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction

Natural Products Targeting Human Lactate Dehydrogenases for Cancer Therapy: A Mini Review

Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy

Small-molecule inhibitors of human LDH5

A patent review of lactate dehydrogenase inhibitors (2014–present)

The effect of lactate dehydrogenase inhibitors on proliferation, motility and invasion of breast cancer cells in vitro highlights a new role for lactate

Targeting Cancer Metabolism to Develop Human Lactate Dehydrogenase ( H LDH)5 Inhibitors

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy

Lactate metabolic pathway regulates tumor cell metastasis and its use as a new therapeutic target

The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies

Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells

Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models

Elucidating the kinetic and thermodynamic insight into regulation of glycolysis by lactate dehydrogenase and its impact on tricarboxylic acid cycle and oxidative phosphorylation in cancer cells

Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH‐A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR

Synthesis and initial screening of lactate dehydrogenase inhibitor activity of 1,3-benzodioxole derivatives

Intervention on lactate in cancer: A promising approach for the development of cancer therapeutics

Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA

Rationale for LDH-Targeted Cancer Immunotherapy

Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach